share_log

Becton, Dickinson and (NYSE:BDX) Releases Quarterly Earnings Results, Beats Expectations By $0.30 EPS

Becton, Dickinson and (NYSE:BDX) Releases Quarterly Earnings Results, Beats Expectations By $0.30 EPS

貝克頓、迪金森及(紐約證交所代碼:BDX)公佈季度盈利業績,超過每股 0.30 美元的預期
Financial News Live ·  2023/02/04 12:42

Becton, Dickinson and (NYSE:BDX – Get Rating) announced its quarterly earnings data on Thursday. The medical instruments supplier reported $2.98 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.30, RTT News reports. Becton, Dickinson and had a return on equity of 13.52% and a net margin of 8.47%. The company had revenue of $4.59 billion during the quarter, compared to analyst estimates of $4.59 billion. During the same quarter last year, the firm posted $3.64 EPS. The firm's revenue for the quarter was down 2.8% on a year-over-year basis. Becton, Dickinson and updated its FY23 guidance to $12.07 to $12.32 EPS and its FY 2023 guidance to $12.07-$12.32 EPS.

週四,Becton、Dickinson和(NYSE:BDX-GET Rating)公佈了季度收益數據。據RTT新聞報道,這家醫療器械供應商公佈了本季度每股收益2.98美元,比普遍預期的2.68美元高出0.30美元。Becton、Dickinson和擁有13.52%的股本回報率和8.47%的淨利潤率。該公司本季度營收為45.9億美元,而分析師預期為45.9億美元。去年同一季度,該公司公佈的每股收益為3.64美元。該公司本季度的收入同比下降了2.8%。並將其23財年每股收益指引更新為12.07美元至12.32美元,將2023財年每股收益指引更新為12.07美元至12.32美元。

Becton, Dickinson and Trading Down 1.1 %

Becton,Dickinson和Trading下跌1.1%

BDX stock traded down $2.63 during trading on Friday, hitting $245.84. 2,117,947 shares of the company traded hands, compared to its average volume of 1,115,617. The firm has a market capitalization of $69.88 billion, a PE ratio of 46.38, a P/E/G ratio of 2.13 and a beta of 0.54. Becton, Dickinson and has a 1 year low of $215.90 and a 1 year high of $280.62. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.63 and a current ratio of 1.07. The company has a 50-day moving average of $251.67 and a 200-day moving average of $244.48.

在週五的交易中,BDX的股價下跌了2.63美元,跌至245.84美元。該公司有2,117,947股易手,而其平均成交量為1,115,617股。該公司市值為698.8億美元,市盈率為46.38,市盈率為2.13,貝塔係數為0.54。貝頓,迪金森,並有一年的低點215.90美元和一年的高點280.62美元。該公司的負債權益比率為0.56,速動比率為0.63,流動比率為1.07。該公司的50日移動均線切入位在251.67美元,200日移動均線切入位在244.48美元。

Get
到達
Becton Dickinson and
貝頓·狄金森和
alerts:
警報:

Becton, Dickinson and Announces Dividend

Becton,Dickinson和宣佈分紅

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 31st. Stockholders of record on Friday, March 10th will be issued a $0.91 dividend. The ex-dividend date is Thursday, March 9th. This represents a $3.64 dividend on an annualized basis and a dividend yield of 1.48%. Becton, Dickinson and's payout ratio is 68.68%.

該公司最近還披露了季度股息,將於3月31日(星期五)支付。3月10日(星期五)登記在冊的股東將獲得0.91美元的股息。除息日期為3月9日(星期四)。這意味着年化股息為3.64美元,股息收益率為1.48%。Becton,Dickinson and的派息率為68.68%。

Analyst Upgrades and Downgrades

分析師升級和下調評級

A number of research firms recently weighed in on BDX. Cowen reduced their price objective on shares of Becton, Dickinson and to $255.00 in a research note on Wednesday, November 16th. Bank of America upgraded Becton, Dickinson and from a "neutral" rating to a "buy" rating and lifted their price target for the company from $250.00 to $290.00 in a research report on Tuesday, January 3rd. Morgan Stanley lifted their target price on Becton, Dickinson and from $290.00 to $295.00 and gave the company an "overweight" rating in a report on Friday. The Goldman Sachs Group reduced their price objective on shares of Becton, Dickinson and from $319.00 to $272.00 and set a "buy" rating for the company in a research note on Wednesday, November 23rd. Finally, StockNews.com raised shares of Becton, Dickinson and from a "hold" rating to a "buy" rating in a research note on Friday. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Becton, Dickinson and has an average rating of "Moderate Buy" and an average target price of $275.64.
最近,一些研究公司也加入了BDX的行列。考恩在11月16日星期三的一份研究報告中將他們對Becton,Dickinson的股票目標價下調至255.00美元。美國銀行在1月3日週二的一份研究報告中將Becton、Dickinson和的評級從中性上調至買入,並將他們對該公司的目標價從250.00美元上調至290.00美元。摩根士丹利在週五的一份報告中將貝克頓、迪金森和貝克漢姆的目標價從290.00美元上調至295.00美元,並給予該公司“增持”評級。11月23日,高盛夫婦在一份研究報告中將他們對貝克頓、狄金森和貝克漢姆的股票目標價從319.00美元下調至272.00美元,併為該公司設定了買入評級。最後,StockNews.com在週五的一份研究報告中將Becton、Dickinson的股票評級從持有上調至買入。三名投資分析師對該股的評級為持有,六名分析師對該股的評級為買入。根據MarketBeat.com的數據,Becton、Dickinson和的平均評級為“中等買入”,平均目標價為275.64美元.

Institutional Trading of Becton, Dickinson and

貝頓、迪金森和

A number of institutional investors have recently modified their holdings of BDX. Kayne Anderson Rudnick Investment Management LLC lifted its position in Becton, Dickinson and by 18.2% during the third quarter. Kayne Anderson Rudnick Investment Management LLC now owns 94,253 shares of the medical instruments supplier's stock valued at $21,003,000 after buying an additional 14,501 shares during the period. Captrust Financial Advisors raised its position in Becton, Dickinson and by 7.3% in the 3rd quarter. Captrust Financial Advisors now owns 87,783 shares of the medical instruments supplier's stock worth $19,561,000 after buying an additional 5,986 shares during the last quarter. CreativeOne Wealth LLC raised its holdings in shares of Becton, Dickinson and by 6.5% during the third quarter. CreativeOne Wealth LLC now owns 2,565 shares of the medical instruments supplier's stock valued at $572,000 after purchasing an additional 157 shares during the last quarter. Jane Street Group LLC increased its position in Becton, Dickinson and by 136.7% during the third quarter. Jane Street Group LLC now owns 34,591 shares of the medical instruments supplier's stock valued at $7,708,000 after acquiring an additional 19,978 shares during the last quarter. Finally, Wealthsource Partners LLC purchased a new stake in Becton, Dickinson and during the third quarter valued at approximately $208,000. 87.08% of the stock is currently owned by hedge funds and other institutional investors.

一些機構投資者最近調整了對BDX的持股。Kayne Anderson Rudnick Investment Management LLC在第三季度將其在Becton,Dickinson的頭寸提高了18.2%。Kayne Anderson Rudnick Investment Management LLC現在持有這家醫療器械供應商94,253股股票,價值21,003,000美元,在此期間又購買了14,501股。CapTrust Financial Advisors在第三季度將其在Becton,Dickinson的頭寸提高了7.3%。CapTrust Financial Advisors現在擁有這家醫療器械供應商87,783股股票,價值19,561,000美元,上個季度又購買了5,986股。CreativeOne Wealth LLC在第三季度增持了Becton,Dickinson的股票,並增加了6.5%的股份。CreativeOne Wealth LLC現在擁有這家醫療器械供應商2,565股股票,價值572,000美元,上個季度又購買了157股。簡街集團在第三季度增加了其在貝頓,迪金森的頭寸,增加了136.7%。簡街集團現在擁有這家醫療器械供應商34,591股股票,價值7,708,000美元,在上個季度額外收購了19,978股。最後,Wealthource Partners LLC在第三季度購買了Becton,Dickinson的新股份,價值約20.8萬美元。87.08%的股票目前由對衝基金和其他機構投資者持有。

Becton, Dickinson and Company Profile

貝頓、狄金森和公司簡介

(Get Rating)

(獲取評級)

Becton, Dickinson & Co engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery.

Becton,Dickinson&Co從事醫療用品、設備、實驗室設備和診斷產品的開發、製造和銷售。它通過以下部門開展業務:BD醫療、BD生命科學和BD Intervative。BD醫療部門生產醫療技術和設備,用於幫助改善醫療保健服務。

Featured Articles

專題文章

  • Get a free copy of the StockNews.com research report on Becton, Dickinson and (BDX)
  • MarketBeat Week in Review – 1/30 – 2/3
  • Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
  • Zimmer Biomet Beats on Earnings, Growth May be Priced In
  • AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
  • Ford Stock Going Forward After Big Earnings Flop
  • 免費獲取StockNews.com關於Becton、Dickinson和(BDX)的研究報告
  • 市場回顧周-1/30-2/3
  • 細價股值得嗎?你應該投資細價股嗎?
  • Zimmer Biomet盈利節節攀升,增長可能被計入價格
  • 人工智能軟件製造商EPAM號稱科技板塊漲幅最大
  • 福特股票在盈利大幅下滑後繼續前進

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

接受Becton Dickinson和Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Becton Dickinson和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論